The Current Ratio as of November 2024 (TTM) for Phathom Pharmaceuticals, Inc. (PHAT) is 5.73

According to Phathom Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 5.73. This represents a change of -24.38% compared to the average of 7.57 of the last 4 quarters.

Phathom Pharmaceuticals, Inc. (PHAT) Historical Current Ratio (quarterly & annually)

How has PHAT Current Ratio performed in the past?

The mean historical Current Ratio of Phathom Pharmaceuticals, Inc. over the last ten years is 16.68. The current 5.73 Current Ratio has changed 3.33% with respect to the historical average. Over the past ten years (40 quarters), PHAT's Current Ratio was at its highest in in the December 2019 quarter at 68.20. The Current Ratio was at its lowest in in the March 2018 quarter at 0.

Phathom Pharmaceuticals, Inc. (PHAT) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Phathom Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Phathom Pharmaceuticals, Inc. (PHAT) Average Current Ratio

How has PHAT Current Ratio performed in the past?

The current Current Ratio of Phathom Pharmaceuticals, Inc. (PHAT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Phathom Pharmaceuticals, Inc. (PHAT) Current Ratio vs. Peers

How is PHAT’s Current Ratio compared to its peers?

Phathom Pharmaceuticals, Inc.’s Current Ratio is less than Day One Biopharmaceuticals, Inc. (14.62), greater than Blueprint Medicines Corporation (3.32), greater than Lyra Therapeutics, Inc. (3.64), less than Cullinan Oncology, Inc. (24.46), less than Acumen Pharmaceuticals, Inc. (10.43), greater than X4 Pharmaceuticals, Inc. (4.89), less than Inozyme Pharma, Inc. (7.68), less than VectivBio Holding AG (9.14), greater than Kiniksa Pharmaceuticals, Ltd. (3.24), less than Structure Therapeutics Inc. (27.63), less than Karuna Therapeutics, Inc. (19.31), greater than Immix Biopharma, Inc. (3.47), greater than CNS Pharmaceuticals, Inc. (1.82), greater than Hepion Pharmaceuticals, Inc. (1.30), greater than Freeline Therapeutics Holdings plc (1.95), less than AVROBIO, Inc. (26.17), less than Terns Pharmaceuticals, Inc. (32.99), greater than Amylyx Pharmaceuticals, Inc. (4.55),

Build a custom stock screener for Phathom Pharmaceuticals, Inc. (PHAT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Phathom Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Phathom Pharmaceuticals, Inc. (PHAT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Phathom Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.